Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.
2.

Novel roles of cAMP/cGMP-dependent signaling in platelets.

Smolenski A.

J Thromb Haemost. 2012 Feb;10(2):167-76. doi: 10.1111/j.1538-7836.2011.04576.x. Review.

3.

Taming platelets with cyclic nucleotides.

Schwarz UR, Walter U, Eigenthaler M.

Biochem Pharmacol. 2001 Nov 1;62(9):1153-61. Review.

PMID:
11705448
4.

Role of cyclic nucleotide-dependent protein kinases and their common substrate VASP in the regulation of human platelets.

Walter U, Eigenthaler M, Geiger J, Reinhard M.

Adv Exp Med Biol. 1993;344:237-49. Review.

PMID:
8209791
5.

Protease-activated receptors in cardiovascular diseases.

Leger AJ, Covic L, Kuliopulos A.

Circulation. 2006 Sep 5;114(10):1070-7. Review.

6.

G-protein-coupled receptors as signaling targets for antiplatelet therapy.

Smyth SS, Woulfe DS, Weitz JI, Gachet C, Conley PB, Goodman SG, Roe MT, Kuliopulos A, Moliterno DJ, French PA, Steinhubl SR, Becker RC; 2008 Platelet Colloquium Participants.

Arterioscler Thromb Vasc Biol. 2009 Apr;29(4):449-57. doi: 10.1161/ATVBAHA.108.176388. Epub 2008 Nov 20. Review.

7.

Inhibitors of platelet signal transduction as anti-aggregatory drugs.

Geiger J.

Expert Opin Investig Drugs. 2001 May;10(5):865-90. Review.

PMID:
11322863
8.

cGMP and cGMP-dependent protein kinase in platelets and blood cells.

Walter U, Gambaryan S.

Handb Exp Pharmacol. 2009;(191):533-48. doi: 10.1007/978-3-540-68964-5_23. Review.

PMID:
19089344
9.

How the protease thrombin talks to cells.

Coughlin SR.

Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11023-7. Review.

10.

Regulators of platelet cAMP levels: clinical and therapeutic implications.

NoƩ L, Peeters K, Izzi B, Van Geet C, Freson K.

Curr Med Chem. 2010;17(26):2897-905. Review.

PMID:
20858171
11.

Protease activated receptors 1 and 4 govern the responses of human platelets to thrombin.

Ofosu FA.

Transfus Apher Sci. 2003 Jun;28(3):265-8. Review.

PMID:
12725953
12.

RWJ-58259: a selective antagonist of protease activated receptor-1.

Damiano BP, Derian CK, Maryanoff BE, Zhang HC, Gordon PA.

Cardiovasc Drug Rev. 2003 Winter;21(4):313-26. Review.

PMID:
14647534
13.

Rationale for the combination of anti-aggregating drugs.

Herman AG.

Thromb Res. 1998 Sep 15;92(1 Suppl 1):S17-21. Review.

PMID:
9781833
14.

Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.

Jennings LK.

Thromb Haemost. 2009 Aug;102(2):248-57. doi: 10.1160/TH09-03-0192. Review.

PMID:
19652875
15.

Discovery of potent peptide-mimetic antagonists for the human thrombin receptor, protease-activated receptor-1 (PAR-1).

Maryanoff BE, Zhang HC, Andrade-Gordon P, Derian CK.

Curr Med Chem Cardiovasc Hematol Agents. 2003 Mar;1(1):13-36. Review.

PMID:
15317288
16.

Protease-activated receptors: new concepts in regulation of G protein-coupled receptor signaling and trafficking.

Trejo J.

J Pharmacol Exp Ther. 2003 Nov;307(2):437-42. Epub 2003 Sep 9. Review.

17.

Role of platelets in atherothrombosis.

Jennings LK.

Am J Cardiol. 2009 Feb 2;103(3 Suppl):4A-10A. doi: 10.1016/j.amjcard.2008.11.017. Review.

PMID:
19166707
18.

Mechanisms of platelet activation by thrombin: a short history.

De Candia E.

Thromb Res. 2012 Mar;129(3):250-6. doi: 10.1016/j.thromres.2011.11.001. Epub 2011 Dec 2. Review.

PMID:
22137742
19.

Cyclic nucleotides in platelet function.

Haslam RJ, Davidson MM, Fox JE, Lynham JA.

Thromb Haemost. 1978 Oct 31;40(2):232-40. Review.

PMID:
216130
20.

Nucleotide receptor signaling in platelets.

Kahner BN, Shankar H, Murugappan S, Prasad GL, Kunapuli SP.

J Thromb Haemost. 2006 Nov;4(11):2317-26. Review.

Supplemental Content

Support Center